Literature DB >> 12490589

Potentiation of anandamide effects in mesenteric beds isolated from endotoxemic rats.

María Luz Orliac1, Roxana Peroni, Stella M Celuch, Edda Adler-Graschinsky.   

Abstract

The aim of the present experiments was to study the effects of exogenously added anandamide on transient norepinephrine (NE)-induced contractions in mesenteric beds isolated from adult male Sprague-Dawley rats 6 h after the i.p. administration of 5 mg kg(-1) lipopolysaccharide (LPS). LPS treatment induced a 3-fold increase in total nitric-oxide synthase (NOS) activity without modifying either the systolic blood pressure or the vascular reactivity to NE of the isolated mesenteric bed. The endocannabinoid anandamide (0.01-10 microM) caused concentration-dependent reductions of the contractile responses to NE in the isolated mesenteric bed. This effect was significantly potentiated after LPS treatment compared with the controls. Anandamide-induced reductions of the contractile responses to NE in mesenteric beds isolated from LPS-treated rats were unmodified by endothelium removal but significantly diminished by either the anandamide amidase inhibitor phenylmethylsulfonyl fluoride (200 microM) or the vanilloid receptor antagonist capsazepine (1 microM). The vanilloid receptor agonist capsaicin (0.01-100 nM) also caused concentration-dependent relaxations that were potentiated in mesenteric beds from LPS-treated rats. Nevertheless, they were unmodified by 1 microM capsazepine. It is concluded that the potentiation of anandamide relaxations after LPS treatment, which are evident at early stages of endotoxic shock, could involve the participation of an anandamide metabolite and might be mediated, at least in part, through a vanilloid receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12490589     DOI: 10.1124/jpet.102.041095

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats.

Authors:  Grzegorz Godlewski; Barbara Malinowska; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

2.  Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

Authors:  Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

Review 3.  Endocannabinoids in liver disease.

Authors:  Joseph Tam; Jie Liu; Bani Mukhopadhyay; Resat Cinar; Grzegorz Godlewski; George Kunos
Journal:  Hepatology       Date:  2011-01       Impact factor: 17.425

Review 4.  Cardiovascular pharmacology of cannabinoids.

Authors:  P Pacher; S Bátkai; G Kunos
Journal:  Handb Exp Pharmacol       Date:  2005

Review 5.  Anandamide and vanilloid TRPV1 receptors.

Authors:  Ruth A Ross
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

6.  Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Authors:  V E Mendizábal; E Adler-Graschinsky
Journal:  Br J Pharmacol       Date:  2007-04-23       Impact factor: 8.739

7.  Transient receptor potential vanilloid 1 antagonist, capsazepine, improves survival in a rat hemorrhagic shock model.

Authors:  Hiroya Akabori; Hiroshi Yamamoto; Hiroshi Tsuchihashi; Tsuyoshi Mori; Kazunori Fujino; Tomoharu Shimizu; Yoshihiro Endo; Tohru Tani
Journal:  Ann Surg       Date:  2007-06       Impact factor: 12.969

Review 8.  Parameters of the Endocannabinoid System as Novel Biomarkers in Sepsis and Septic Shock.

Authors:  J Daniel Lafreniere; Christian Lehmann
Journal:  Metabolites       Date:  2017-11-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.